Letter to the EditorSafety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease
Cited by (0)
Disclosure of potential conflict of interest: R. Caorsi receives speaker’s fees and has consultancies for Novartis and SOBI. A. Ravelli receives speaker’s fees and has consultancies for Novartis and SOBI. M. Gattorno receives speaker’s fees and has consultancies for Novartis and SOBI. The rest of the authors declare that they have no relevant conflicts of interest.
- ∗
These authors contributed equally to this work.
© 2020 American Academy of Allergy, Asthma & Immunology